|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a single center, double-blinded, placebo-controlled phase I clinical trail in healthy volunteer of meplazumab for injection. The primary objective of this phase I trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and occupancy characteristics of peripheral blood cell receptors of meplazumab in healthy volunteer, and provide a reference for the dosage of meplazumab in phase II clinical trial.
Description: Nature, incidence, and severity of AEs/SAEs, and the relationship to meplazumab treatment.Measure: Incidence rate of treatment-related adverse events as assessed by CTCAE v5.0 Time: 0-28 days
Description: AUC0-tnMeasure: Pharmacokinetic assessments of meplazumab- AUC0-tn Time: 0-28 days
Description: AUC0-∞Measure: Pharmacokinetic assessments of meplazumab- AUC0-∞ Time: 0-28 days
Description: Maximum observed plasma concentration of meplazumab (Cmax)Measure: Pharmacokinetic assessments of meplazumab-Cmax Time: 0-28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports